You’re invited to a symposium on colon health.

COLORECTAL CANCER SYMPOSIUM 2019: From Early Detection to Survivorship

An update for the primary care physician and registered nurse

Saturday, April 27, 2019 7:45 a.m. - 12:45 p.m.

Register online at care.honorhealth.com/colorectal-cancer-symposium-2019

This CME event is not supported by any commercial entity or joint partnership.

12778_0219

Col

on H

ealth

Sym

pos

ium

Ho

norH

ealth

invi

tes

you

to a

co

lore

ctal

can

cer

sym

po

sium

fr

om

7:4

5 a

.m.-1

2:4

5 p

.m. S

atur

day

, Ap

ril 2

7.

The

sym

po

sium

focu

ses

on

criti

cal i

nfo

rmat

ion

you

need

to k

now

as

a p

rim

ary

care

pro

vid

er, i

nclu

din

g:

• Im

agin

g a

nd g

enet

ic te

stin

g in

ea

rly

det

ectio

n.

• Su

rgic

al tr

eatm

ent a

nd o

ptio

ns.

• M

edic

al o

nco

log

y st

and

ard

s

of c

are.

• C

olo

rect

al c

linic

al re

sear

ch.

PO B

OX

905

4 PH

OEN

IX, A

Z 85

068

-905

4

Cha

teau

Lux

e 11

75 E

. Lo

ne C

actu

s D

rive

Pho

enix

, AZ

8502

4E.

LONE

CACTU

S DR.

E. DE

ER VA

LLEY

DR.

N. 7TH STREET

Reg

iste

r o

nlin

e at

car

e.ho

norh

ealth

.co

m/c

olo

rect

al-c

ance

r-sy

mp

osi

um-2

01

9Th

is c

onf

eren

ce h

as b

een

app

rove

d b

y th

e A

SRT

for

6 C

ateg

ory

A C

E’s.

Att

end

ees

mus

t be

pre

sent

for

all

lect

ures

to re

ceiv

e cr

edit.

HonorHealth 2019 Colorectal Cancer Symposium

Acknowledgment: This CME event is not supported by any commercial entity or joint partnership.

Disclosure: Dr. Sharma discloses that he has received grant/research support from Toray Industries, Celgene, Hengrui, OncoMed, Plexxikon, Tesaro, AADi, Syndax, and Merck, is a stock/shareholder of Beta Cat Pharmaceuticals, Salarius Pharmaceuticals, ConverGene, Stingray Therapeutics, and Proterus Therapeutics, and that he received honoraria from Loxo Oncology, Exelixis, Hengrui Therapeutics, Tarveda Therapeutics, and Dracen Pharmaceuticals. Sarah Highlander, PhD, discloses that she has received grant/research support from University of Southern California. All other speakers and members of the planning committee have no relevant financial relationships with a commercial interest to disclose.

Accreditation Statement: HonorHealth is accredited by the Arizona Medical Association to provide continuing medical education for physicians.

Credit Statement: HonorHealth designates this live activity for a maximum of _3.25_ AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

, MS

PRESENTATION TOPICSCOLON CANCER: From Early Detection to Survivorship

Michael Gordon, MD

Paul Sieckmann, MD

Cory R. Fraser, MD Dana Brown, MSC

Acknowledgment: This CME event is not supported by any commercial entity or joint partnership.

Disclosure: Dr. Sharma discloses that he has received grant/research support from Toray Industries, Celgene, Hengrui, OncoMed, Plexxikon, Tesaro, AADi, Syndax, and Merck, is a stock/shareholder of Beta Cat Pharmaceuticals, Salarius Pharmaceuticals, ConverGene, Stingray Therapeutics, and Proterus Therapeutics, and that he received honoraria from Loxo Oncology, Exelixis, Hengrui Therapeutics, Tarveda Therapeutics, and Dracen Pharmaceuticals. Sarah Highlander, PhD, discloses that she has received grant/research support from University of Southern California. All other speakers and members of the planning committee have no relevant financial relationships with a commercial interest to disclose.

Accreditation Statement: HonorHealth is accredited by the Arizona Medical Association to provide continuing medical education for physicians.

Credit Statement: HonorHealth designates this live activity for a maximum of _3.25_ AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sunil Sharma, MD

SYMPOSIUM PRESENTERS

Deepa Shah, MD

Welcome and opening remarks Sunil Sharma, MD, FACP, MBA Chief, Translational Oncology Research & Drug Discovery HonorHealth Research Institute

Conference Director

Paul Sieckmann, MD, Primary Care Physician Chief Medical Officer, HonorHealth Medical Group

Colorectal cancer (CRC) care from the Primary Care perspective.

OBJECTIVES: ■ Discuss the role of the Primary Care Provider in

CRC detection.

■ Describe patient-risk assessment for CRC from the Primary Care perspective.

Deepa Shah, MD, FACG, Gastroenterologist

Role of the Gastroenterologist in colorectal cancer detection and treatment

OBJECTIVES: ■ Review evidence-based CRC screening

guidelines including opportunities and challenges of screening at 45 vs 50.

■ Discuss the goals of routine screening by colonoscopy and recent advancements in CRC screening. Review HonorHealth CRC Screening guidelines.

Phillip Moeser, MD, Radiologist

Imaging of Colorectal Cancer

OBJECTIVES: ■ Explain the role of imaging in the detection,

clinical staging and treatment assessment of CRC.

■ Describe the importance of MRI in rectal tumor imaging.

Neeraj Singh, MD, Colorectal Surgeon

Surgical approaches to CRC treatment

OBJECTIVES: ■ Review current surgical treatments for CRC.

■ Outline the role of minimally invasive surgery.

■ Identify surgical treatment options for patients with limited metastatic disease.

■ Discuss enhanced patient recovery after colon surgery.

Cory R. Fraser, MD, Pathologist

Pathologic diagnosing and molecular testing of CRC

OBJECTIVES: ■ Summarize the pathologic evaluation and

staging of CRC.

■ Review the implications of molecular testing in CRC as it relates to targeted therapy.

Sarah Highlander, PhD

Neeraj Singh, MD

Terri Taylor, RD, CSODawn Bassett, RN Phillip Moeser, MD

Michael Gordon, MD, Medical Oncologist

Treatment options for CRC patients

OBJECTIVES: ■ Discuss current CRC therapies based on

evidence-based national guidelines and prognostic indicators.

■ Describe new approaches to CRC treatment.

Sunil Sharma, MD, FACP, MBA, Research, Medical Oncologist, Chief, Translational Oncology Research & Drug Discovery, HonorHealth Research Institute

New treatments for patients with CRC

OBJECTIVES: ■ Discuss the opportunities for clinical trials in the

treatment of CRC.

■ Summarize how CRC patients should be introduced to clinical trials.

■ Discuss importance of early detection and recognizing the high risk patient.

Terri Taylor, RD, CSO

Diet and nutrition as it relates to CRC

OBJECTIVES: ■ Review diet recommendations to reduce CRC

risk.

■ Discuss nutrition recommendations during and after treatment for CRC.

Keynote Speaker: Sarah Highlander, PhD, Director, TGen Clinical Microbiome Services Center

The human microbiome and its emerging role in health and disease: focus on colon cancer

OBJECTIVES: ■ Identify the importance of the microbiome as it

relates to health, disease and colon cancer.

Dana Brown, MSC, Certified Genetic Counselor

Familial susceptibility of CRC patients and their family.

OBJECTIVES: ■ Summarize the role of the genetic counselor in

the evaluation of individuals at risk for CRC.

■ Outline the use of genetic testing in patients with CRC.

Dawn Bassett, MSN, Ed, RN, OCN, Oncology Nurse Navigator

Role of the Nurse Navigator in CRC care

OBJECTIVES: ■ Explain the role of the nurse navigator and the

benefits to patients/ caregivers.

■ Express how navigation can improve patient outcomes.

CONFERENCE DIRECTOR KEYNOTE SPEAKER